Allogene's Q3 Loss Narrower Than Expected, Sales Nil [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Inclusive of impairment charges, the company posted a loss of 32 cents per share in the quarter. In the year-ago period, the company reported a loss of 37 cents. There was no impairment charge in the year-ago period. Allogene did not generate revenues during the reported quarter. The Zacks Consensus Estimate for third-quarter sales was pegged at $0.04 million. In the year-ago period, management recorded revenues of $0.02 million. Year to date, shares of Allogene have lost 0.6% compared with the industry's 2.4% decline. Image Source: Zacks Investment Research Research & development (R&D) expenses totaled $44.7 million, down 3% from the year-ago quarter's level. General and administrative (G&A) expenses declined 4% year over year to $16.3 million. As of Sept. 30, 2024, Allogene had $403.4 million of cash, cash equivalents and investments, compared with $444.6 million as of June 30, 2024. Management claims that this cash will help the company extend its cash runway into the
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Announces Participation in December Investor ConferencesGlobeNewswire
- Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) ConvergenceGlobeNewswire
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Piper Sandler from $11.00 to $9.00. They now have an "overweight" rating on the stock.MarketBeat
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 11/13/24 - Form 8-K
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- ALLO's page on the SEC website